ALK fusion is an important driver mutation that accounts for approximately 3-7% of non-small cell lung cancer (NSCLC) cases (2–4), and the most common form is EML4-ALK (5, 6). The gene discussed is EML4; the disease is non-small cell lung carcinoma.